7th Annual Fellows Forum in Breast Oncology

7th Annual Fellows Forum in Breast Oncology

Engaging the Next Generation of Oncology Leaders

Not a member of My prIME? Join now for instant access.

Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.

Meeting Overview

This educational activity is designed for physicians in training in the area of breast cancer and features case presentations by fellows from four academic training centers. Following each fellow presentation, an affiliate faculty member will discuss the case and a multidisciplinary panel discussion will follow. This rare and highly educational opportunity will allow for the research interests of participating faculty to be an integral part of the discussion and gives physicians in training the opportunity to interact with high-level experts in breast cancer.

This is intended to be an interactive activity. Please come prepared to engage in the program.

Date and Location

Friday, June 1, 2018
8.30 AM – 9.00 AM Breakfast and registration
9.00 AM – 1.00 PM Educational session

Hyatt Regency McCormick Place
Hyde Park/ CC11 – 1st Floor Conference Center
2233 South Dr Martin Luther King Jr Drive
Chicago, Illinois 60616



Friday, June 1, 2018
8.30 AM - 1.00 PM



Chicago, Illinois, United States



3.5 AMA PRA Category 1 Credits™

8.30 AM Breakfast
9.00 AM Welcome and introduction of faculty
Larry Norton, MD, and Martine Piccart, MD, PhD
9.05 AM Case #1—Adjuvant hormonal therapy for premenopausal breast cancer
Fellow Presenter: Ana Garrido-Castro, MD, Dana-Farber Cancer Institute
Faculty Discussant: Harold J. Burstein, MD, PhD
9.55 AM Case #2—Hormonal therapy for advanced premenopausal breast cancer
Fellow Presenter: Katherine Clifton, MD, The University of Texas MD Anderson Cancer Center
Faculty Discussant: Debu Tripathy, MD
10.45 AM Coffee break
11.15 AM Case #3—Neoadjuvant and adjuvant treatment options for a patient with triple-negative breast cancer and a BRCA mutation
Fellow Presenter: Giulia Viale, MD, European Institute of Oncology
Faculty Discussant: Giuseppe Curigliano, MD, PhD
12.05 PM Case #4—Recurrent triple-negative breast cancer in a patient with a BRCA mutation
Fellow Presenter: Tomas Lyons, MD, Memorial Sloan Kettering Cancer
Faculty Discussant: Mark Robson, MD
12.55 PM Program summary and concluding remarks
Larry Norton, MD, and Martine Piccart, MD, PhD
1.00 PM Adjourn

Registration for this event is required and there is no cost to attend. To assist with your travel costs related to attending this meeting, attendees will be given a $300 travel stipend at the end of the event.

Upon completion of your registration, your confirmation email will contain a link to a form to complete in order to receive your travel stipend. Please complete this prior to attending the event.


  • Larry Norton, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Martine Piccart, MD, PhDJules Bordet Institute
    Brussels, Belgium
  • Faculty

  • Harold J. Burstein, MD, PhDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Giuseppe Curigliano, MD, PhDEuropean Institute of Oncology
    University of Milan
    Milan, Italy
  • Jorge Reis-Filho, MD, PhD, FRCPathMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Mark Robson, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Debu Tripathy, MDThe University of Texas M. D. Anderson Cancer Center
    Houston, Texas
  • Fellow Presenters

  • Katherine Clifton, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Ana Garrido-Castro, MDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Tomas Lyons, MB, BCh, BAO, MRCPIMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Giulia Viale, MDEuropean Institute of Oncology
    Milan, Italy

This educational activity is specifically designed for physicians in training in medical oncology who are interested in breast cancer.

Upon completion of this educational activity, participants should be able to:

  • Describe recent findings from ongoing clinical trials of new therapeutic options for breast cancer
  • Identify unmet needs in breast cancer research and treatment
  • Select optimal therapies for individual patients with breast cancer from among the available and emerging strategies

This educational activity is supported by a grant from Breast Cancer Research Foundation.


Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

7th Annual Fellows Forum in Breast Oncology - prIME Oncology

prIME Oncology designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.